Temporal trends in heart failure medication prescription in a population-based cohort study

Alicia Uijl1,2,3,4, Ilonca Vaartjes5, S Denaxas3,4,6,7

  • 1Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands a.uijl@umcutrecht.nl.

BMJ Open
|March 3, 2021
PubMed

Insights

Heart failure (HF) medication patterns show increased beta-blocker use but stagnant mineralocorticoid receptor-antagonist prescriptions. Few changes in HF drug management occurred within six months of diagnosis.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Heart failure (HF) management relies on timely pharmacological intervention.
  • Understanding temporal prescription trends is crucial for optimizing patient care and outcomes.

Purpose of the Study:

  • To analyze the trends in heart failure (HF) medication prescriptions over a 13-year period in the UK.
  • To identify patterns in the pharmacological management of HF in a real-world patient cohort.

Main Methods:

  • Utilized electronic health records (EHR) from primary and secondary care in the UK.
  • Identified 85,732 patients diagnosed with HF between 2002 and 2015.
  • Examined prescription patterns for key HF medications over time and by patient demographics.

Main Results:

  • Beta-blocker prescriptions increased significantly from 29% to 54% between 2002-2005 and 2013-2015.
  • Mineralocorticoid receptor-antagonist (MR-antagonist) prescriptions remained low and unchanged (18%) throughout the study period.
  • Women and elderly patients showed lower prescription rates for several key HF medications, and patients without primary care follow-up had reduced prescription rates.

Conclusions:

  • Despite increased beta-blocker use, MR-antagonist utilization for HF remains suboptimal and static.
  • Pharmacological management of HF shows limited changes within the initial six months post-diagnosis.
  • Real-world data highlights disparities in HF medication prescribing, particularly for women and the elderly.
Abstract

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
85
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
128
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
552
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
241
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
102